Company news

Camurus AB news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Camurus receives approval in Canada for Oczyesa XR, a once-monthly, self-administered treatment for acromegaly

October 12, 2026

Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA

July 17, 2026

Camurus' Interim Report Second Quarter 2026

July 15, 2026

Change in number of shares and votes in Camurus

June 30, 2026

Camurus provides regulatory update on the US NDA for CAM2029 (Oclaiz™) in acromegaly

June 10, 2026

AGM Minutes 2026 (agm minutes 2026)

June 1, 2026

CEO Presentation (ceo presentation)

May 29, 2026

Camurus' Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company's commitments under the Performance Share Plan 2026/2029

May 28, 2026

Camurus' Interim Report January-March 2026

May 12, 2026

Proposal by the Board of Directors on the implementation of a Performance Share Plan 2026/2029

April 29, 2026

Proposal by the BoD on authorization for the Board of Directors to resolve on issues of new shares and convertibles

April 29, 2026

Proposal by the Board of Directors on authorization for the Board of Directors to resolve on acquisition and transfer of own shares

April 29, 2026

Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer

February 17, 2026

Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly

January 9, 2026

Camurus reports positive topline results for CAM2056, semaglutide monthly depot

November 10, 2025

Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK

August 28, 2025

Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU

July 1, 2025

Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients

June 18, 2025

Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

June 3, 2025

CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU

April 25, 2025

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 54 decks. Every deck is listed under its year.